2023-05-08
大湾生物跻身2023未来医疗100强•中国创新医疗商业及供应链服务榜TOP100榜单

Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026
2026-08-12

AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel
2026-08-07

Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published
2026-07-17